《临床及应用血栓/止血》(CATH)的每一期都针对管理出血和凝血障碍，特别是与血栓形成、止血和血管疾病相关的临床和实验室实际问题。CATH提供对您的工作最重要的主题的全面覆盖，包括临床试验、病因学研究、病理生理学、血栓出血疾病的诊断和治疗、新临床诊断程序的评估、药理制剂、实验室诊断程序和患者管理计划。CATH不断评估在华法林、肝素、低分子肝素等基础药物和其他新兴药物治疗领域的新研究;对糖尿病、高血压、妊娠、血友病、HIV-AIDS等疾病和条件治疗的临床影响;因素的缺陷;血小板疾病;溶解纤维蛋白的障碍;DNA / RNA研究;以及不同种族和人群在血栓性失血性疾病方面的差异。
http://mc.manuscriptcentral.com/cath
Every issue of Clinical and Applied Thrombosis/Hemostasis (CATH) addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH offers comprehensive coverage of the topics that matter most to your work, including clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders, assessment of new clinical diagnostic procedures, pharmacological agents, laboratory diagnostic procedures, and patient management plans. CATH continually evaluates new research in areas including essential drugs such as Warfarin, Heparin, low-molecular-weight Heparin, and other emerging drug therapies; the clinical impact on treatment of diseases and conditions such as diabetes, hypertension, pregnancy, hemophilia, and HIV-AIDS; factor defects; platelet disorders; fibrinolytic disorders; DNA/RNA research; and ethnic and population differences in thrombohemorrhagic disorders.
